关键词：导向治疗；乙型肝炎；治疗
【摘要】 目的 为初步试探受体导向药物L-HSA-Ara-AMP的抗病毒效果。方法 应用5天疗法治疗慢性乙型肝炎10例，并以Ara-AMP为对照。结果 治疗组HBsAg无变化，10例HBeAg阳性者阴转3例，滴度下降6例，4例抗-HBc IgM阳性均阴转，8例HBV DNA阳性阴转4例，浓度下降4例，未发现任何毒副反应。结论 显示该药对HBV复制指标的近期抑制效果与Ara-AMP相近或略优，但日剂量仅为后者的1/7。
Preliminary clinic observation on the inhibition of HBV by receptor-targeted drug L-HSA-AraAMP
Wang Huifen, Zhang Lingxia, Wang Xiaoming, et al. 302 Hospital of PLA, Beijing 100039
Abstract To preliminarily observe the antiviral effect of receptor-targeted drug, the Lactosaminated Human Serum Albumin Arabinoside Adenine Monophosphate (L-HSA-Ara-AMP), 10 patients with chronic type B hepatitis (HBsAg、HbeAg/HBV DNA positive) were treated with this drug for 5 days. The daily dose of L-HSA-Ara-AMP was 35mg/Kg (containing 1.5mg Ara-AMP), whereas the usual daily dose of free Ara-AMP is 10mg/Kg. In 10 patients treated, three patients’HBeAg became negative and six patients’ HBeAg titer fell. Anti-HBc IgM all became negative in 4 anti-HBc IgM positive patients. In 8 HBV DNA positive patients, four patients’ HBV DNA became negative and the other four patients’ HBV DNA decreased. HBsAg remained positive in all of the ten patients. No adverse effects were observed. The results showed that L-HSA-Ara-AMP inhibits HBV as effective as free Ara-AMP, but at a daily dose 6.7 times lower than free Ara-AMP.
......
您现在查看是摘要页，全文长 14161 字符。